Hengyi Biotechnology, founded in 2023 and headquartered in Songshan Lake, Dongguan, is an AI-driven synthetic biology platform company focused on the research, development, large-scale manufacturing, and commercialization of recombinant humanized collagen. It is one of the few synthetic biology enterprises in China that has established a fully integrated value chain spanning R&D, manufacturing, and market deployment.
The company has broken through the industry's core technological bottleneck — the triple-helix structure — and is the first Chinese company to receive NIFDC certification for a 90°C thermally reversible triple-helix collagen. It has built its proprietary BEST Platform — an AI-powered digital infrastructure for full-chain R&D and manufacturing — leveraging a large model + multi-agent architecture that integrates 20+ state-of-the-art (SOTA) professional models. The platform covers the entire journey from strain screening and scale-up manufacturing to product launch, making Hengyi one of the few companies in China to achieve a closed industrial loop of "in silico computation → in vitro validation → data feedback → model iteration." Through five R&D modules built on the platform, the company has established a complete R&D cycle spanning "sequence — structure — function — application."
In 2024, Hengyi achieved a technological breakthrough in 90°C thermal stability, scaled up to 3×30-ton fermentation capacity, and received global certification from Frost & Sullivan. In 2026, the company obtained INCI nomenclature registration, was certified as a National High-Tech Enterprise, received its first Class II medical device approval, and initiated clinical trials for its Class III medical device.
The company's products span four major sectors: medical aesthetics, functional skincare, medical devices, and serious medicine. Its proprietary brands have achieved full-channel sales coverage, while the company has also entered into raw material supply partnerships with leading cosmetic brands, becoming an integral part of their core supply chains.
Everon Healthcare Products launched the recombinant type XVII humanized collagen raw material
Recombinant Type III collagen Skin rejuvenation needle, collagen regeneration needle is expected to be launched in 2027
Jinmeiji Group and Dongguan Science and Technology Bureau established Songshan Lake Modern biomedical Industry Technology Research Institute
Jinmeiji Pharmaceutical was established
independent research and development of 4 prescription drugs, series of health products
Dongguan Guangji Hospital under Jinmeiji Group was built
Guangdong Jinmeiji Group Co., Ltd. was established
Guangdong Guangji medical Equipment Co., Ltd. was founded
Jinan University of Business Administration
Director of Jin Mei Ji Group
CEO of Jin Mei Ji Media Technology
Executive Director of Songshan Lake Charity Foundation
PhD in Chemical Engineering from Swansea University
Master of Chemical and Biochemical Engineering
Computational simulation ability: Proficient in programming languages such as MATLAB, FORTRAN, Python, etc,
Develop multiple computational models and apply them to fields such as intermolecular forces on cell surfaces and analysis of hydrophilicity and hydrophobicity
Intersection of AI and Biology: Application and Development of Biomacromolecule Prediction Models; Applying AI technology to the field of biomedicine, including protein structure prediction, molecular docking, microfluidic technology, etc
Senior Engineer PhD in Microbiology
Proficient in the whole process of microbial research and development familiar with gene editing
Postdoctoral Fellow, Chinese Academy of Sciences
Ph.D., Ocean University of China
Shenzhen Overseas High-Caliber Talent
Assistant Professor, George Washington University, USA
Visiting Professor, Shenzhen University Affiliated South China Hospital
Dr. Zhou has published 45 peer-reviewed papers with over 6,000 total citations. He has led multiple national and provincial-level scientific research projects. His expertise lies in tissue and organ regeneration, bioactive materials, and the formulation development and commercialization of medical and aesthetic products.
Doctor of Immunology, Nankai University /Senior Engineer
More than 20 years of genetic engineering and synthetic
PhD in Biomedical AI Chips from The Chinese University of Hong Kong (youngest in history)
Dual Bachelor's degree from Peking University School of Information Science and Technology and Guanghua School of Management
Experience in B-level national key projects, publishing 10 patents
6 chip fabrication experiences (TSMC 22nm, 55nm, 180nm)
Air injection is used to design software and hardware for addressing the sparsity of weights in biomedical AI models
Develop acceleration algorithms and medical grade wearable devices and chips
PhD in Biology from Warsaw University
The research direction is drug delivery and formulation research.
Focusing on the study of cell membrane penetrating peptide CPP as a drug carrier for mediating the transport and delivery of biomolecules in vitro and in vivo.
Immunogenicity of mRNA vaccines synthesized in vitro
Focusing on large-scale proteomics and real-world evidence (RWE) directions;
Skilled in large-scale proteomics reproducibility analysis, applied in scientific research and medical health fields
Guangdong Jinmeiji Group is an enterprise that integrates drug production and R&D, drug distribution and sales, as well as medical services and healthcare within its industrial park. With 29 years of history, the company operates four GMP production lines, several GSP-certified companies, and general hospitals. Drawing on extensive experience in pharmaceutical research, production, management, and marketing, along with a robust quality management system, its subsidiary Everon Healthcare specializes in leading and uniquely crafted recombinant humanized type III collagen technology.
This white book adopts a rigorous scientific approach and a broad industry perspective. It starts by exploring foundational research on collagen, offering a thorough explanation of its definition, classification, structural characteristics, and vital role within the human body. It delves particularly into the discovery and structural features of Type III collagen, highlighting its phenomenal contributions to maintaining skin stability, tissue elasticity, and wound healing. At the same time, we highlight the innovative advancements in recombinant Type III triple-helix collagen technology. This includes its design principles, production methods, and bioactivity assessment, demonstrating the significant advantages of this technology in enhancing purity, safety, and adaptability.
Notably, Everon Healthcare has successfully applied recombinant Type III triple-helix collagen, offering a glimpse into the extensive application potential of this technology. Its prospects span multiple fields, including medical specialties, medical aesthetics, and functional skincare industries. With a fully humanized design, AI-assisted optimization, and high-temperature stable triple-helix structure, Everon Healthcare is at the forefront of industry innovation. These advancements provide patients with safer and more effective treatment options, setting a new standard in the field. It provides more possibilities for those pursuing beauty and health, making beauty more efficient and trustworthy. This trusted ingredient marks the beginning of a new era in humanity's pursuit of beauty, offering unlimited benefits and opportunities to explore aesthetics further.
Looking ahead, the future of recombinant Type III triple-helix collagen technology holds immense promise. As research advances and technology evolves, we are confident that this innovation will showcase its unique value across an even wider range of fields. It has the potential to drive breakthroughs in the medical aesthetics industry and contribute significantly to human health. At Everon Healthcare, we believe this triple-helix ingredient marks the starting point of our journey in synthetic biology, and our goal remains to deliver more groundbreaking raw material technologies to benefit people. Together, let us explore the untapped potential of this field and usher in a new era of health and beauty.
As the General Manager of Everon Healthcare, I am truly honored to be part of this meaningful endeavor. As a member of the Jinmeiji Group, I aspire for our contributions in medicine and pharmaceuticals to explore beyond saving lives and alleviating pain, but also to help sustain and strengthen people’s enduring pursuit of beauty. Medical aesthetics, with safe and reliable ingredients, not only treat physical illnesses but also foster confidence and well-being in our society, propelling human progress in beauty and relaxation. I am confident that the release of the "2024 White Book on Recombinant Type III triple-helix Collagen" will become a significant milestone in advancing this field. Let this be the foundation for continued dedication and progress, as we jointly create a healthier and more beautiful in the future.
—— Aries Yang, Chief Executive Officer of Everon Healthcare
Hengyi Biological official accountCopyright ©2007-2024 All Rights Reserved Dongguan Hengyi Biotechnology Co., Ltd 粤ICP备2024274226号
